Nyxoah (NASDAQ:NYXH) Price Target Lowered to $15.00 at HC Wainwright

Nyxoah (NASDAQ:NYXH) had its target price dropped by stock analysts at HC Wainwright from $17.00 to $15.00 in a report issued on Wednesday,Benzinga reports. The firm currently has a “buy” rating on the stock. HC Wainwright’s target price would indicate a potential upside of 87.50% from the stock’s previous close.

Separately, Stifel Nicolaus dropped their price target on Nyxoah from $16.00 to $15.00 and set a “buy” rating on the stock in a research report on Friday, March 14th.

Nyxoah Stock Down 10.2 %

Shares of NASDAQ:NYXH opened at $8.00 on Wednesday. The company has a 50 day moving average price of $10.42 and a two-hundred day moving average price of $9.34. The company has a debt-to-equity ratio of 0.21, a quick ratio of 4.95 and a current ratio of 5.28. The company has a market capitalization of $272.48 million, a PE ratio of -4.28 and a beta of 1.42. Nyxoah has a 52 week low of $6.76 and a 52 week high of $13.67.

Nyxoah (NASDAQ:NYXH) last released its quarterly earnings data on Thursday, March 13th. The company reported ($0.49) EPS for the quarter, missing analysts’ consensus estimates of ($0.46) by ($0.03). The firm had revenue of $1.35 million during the quarter, compared to the consensus estimate of $2.02 million. Nyxoah had a negative net margin of 1,043.93% and a negative return on equity of 51.68%. Analysts forecast that Nyxoah will post -1.91 earnings per share for the current year.

Institutional Investors Weigh In On Nyxoah

Institutional investors have recently added to or reduced their stakes in the stock. LPL Financial LLC acquired a new stake in shares of Nyxoah in the 4th quarter valued at about $102,000. Walleye Capital LLC grew its holdings in shares of Nyxoah by 23.9% during the fourth quarter. Walleye Capital LLC now owns 14,831 shares of the company’s stock worth $119,000 after buying an additional 2,862 shares in the last quarter. Ameriprise Financial Inc. acquired a new stake in Nyxoah in the 4th quarter valued at approximately $135,000. Geode Capital Management LLC lifted its stake in Nyxoah by 19.4% in the 4th quarter. Geode Capital Management LLC now owns 17,100 shares of the company’s stock valued at $137,000 after acquiring an additional 2,774 shares in the last quarter. Finally, Kovack Advisors Inc. boosted its position in Nyxoah by 100.0% during the 4th quarter. Kovack Advisors Inc. now owns 20,000 shares of the company’s stock worth $160,000 after acquiring an additional 10,000 shares during the last quarter.

About Nyxoah

Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea.